GlobeNewswire

2024-09-27 18:05

Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, disability, and death caused by non-communicable diseases (NCDs). The start of the partnership was announced alongside the United Nations Global Assembly in New York.

NCDs are a major global health issue. These diseases, which are not transmitted from person to person, cause 41 million deaths each year, accounting for 74% of all deaths worldwide.  With at least one in three people living with a NCD and half the world's population lacking essential health services, many are not receiving the care they need.

Within the broad category of NCDs, there are specific types known as Cardiovascular, Renal, and Metabolic (CRM) diseases. These CRM diseases are conditions that specifically impact the heart, kidneys, and the body's metabolism. Affecting over one billion lives globally, CRM diseases are the leading cause of death worldwide, accounting for up to 20 million deaths annually.

Together, Boehringer Ingelheim and the NCD Alliance will drive advocacy to strengthen health systems to respond to NCDs and ensure integration of NCDs within Universal Health Coverage and primary health care, emphasising cardiovascular, renal, and metabolic conditions. The partnership will also strengthen the evidence and advocacy to address inequities in access to NCD care, including reaching the most vulnerable populations and those left behind.

“Through this partnership, we have a unique opportunity to showcase successful examples of health system strengthening for the NCD response, particularly addressing health equity and reaching underserved communities," said Katie Dain, CEO of NCD Alliance. "Our goal is to ensure access to quality care for all, regardless of income or geography”.

Already today, Boehringer helps millions of people worldwide live longer, healthier lives. In line with its sustainability framework “Sustainable Development for Generations”, Boehringer has committed to expand NCD healthcare access for 50 million people in underserved communities and low- and middle-income countries by 2030.

"This partnership couldn't have come at a better time," says Médard Schoenmaeckers, Head of Corporate Affairs. "Together with the NCD Alliance, we are on a mission to overcome barriers to quality care. We believe that where you live or how much you earn shouldn't decide your access to treatment. This collaboration is our commitment to better health systems, to lessen the disease burden, and ultimately, to change the face of global health."

Boehringer Ingelheim’s sustainability strategy addresses health equity and wellbeing across the whole patient continuum of care: from pharmaceutical innovation over prevention and healthcare delivery to tackling equitable access. In particular to improve the lives of people and animals living in underserved communities. Fostering multi-stakeholder collaboration is a key aspect to promote systemic change.

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com

Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.


Primary Logo

source: Boehringer Ingelheim

【香港好去處】2025去邊最好玩?etnet為你提供全港最齊盛事活動,所有資訊盡在掌握!► 即睇

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
3
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
4
財政預算案2025 | 重點文字直播/Youtube直播(稍後送上懶人包)
5
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
6
高息定存 | 一周高息合集,3個月5厘之選有邊間?6個月最高3.55厘
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
9
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
10
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
11
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
12
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
13
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
14
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
15
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
16
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
17
高息定存 | 信銀國際12個月港元定存高達3.5厘
18
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
19
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
20
民營企業座談會 | 習近平在京出席民營企業座談會
21
David Webb:因病情惡化,將有序結束個人財經網站
22
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
23
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
24
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
25
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
26
港股 | 蕭猷華:恒指升勢可持續?
27
美股收盤 | 美股三大指數收市報跌,道指跌近750點
28
比特幣 | 亞洲時段虛擬貨幣大幅下跌,31萬人爆倉
29
神州經脈 | 中國減持美債,螞蟻入局具身智能,70城樓價向好
30
隱瞞「賣殼」欺詐罪成,詹培忠判囚34個月,詹劍崙囚37個月
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

2025-26年度財政預算案

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老